Skip to main content
Nebenniere_Metabolite
Helmholtz Munich | AAP

Research Unit Analytical Pathology

Analytical Pathology builds on clinical pathology and expands it by the inclusion and development of the very latest methods for tissue analysis. Analytical Pathology opens up new directions for reverse translational research, molecular imaging pathology, digital pathology, and machine learning and pathology-related omics data.

 

 

 

 

The Research Unit Analytical Pathology (AAP) carries out scientific development, as a complement to research units with a clinical and fundamental orientation of translational research on diseases that occur in tissue.

About our Research

Our research includes two areas of research activity. One is the process of applying discoveries generated during research in the laboratory, and in preclinical studies, to the development of trials and studies in humans. The second area concerns research aimed at enhancing the adoption of best practices in the community.

 

 

 

 

Research Fields

Heterogeneous distribution of four metabolites in cancer tissue
Helmholtz Munich | AAP

Cancer metabolism and inter-/intratumoral metabolic heterogeneity

Understanding tumor heterogeneity presents one of the most important tasks in cancer research towards improving both diagnosis and treatment of patients. Heterogeneity of tumors contributes to treatment failure and disease recurrence, whereas the interaction between tumor cells and the associated stroma poses novel therapeutic opportunities. Intratumoral heterogeneity refers to the fact that cells within a tumor mass can be highly diverse due to an evolving process in cancer development driven by the stepwise accumulation of molecular changes and clonal selection, while intertumoral heterogeneity describes molecular alterations in several (metastatic) tumors present within or between patients. In malignant cells alteration in molecular features and clonal selection constantly takes place and provides either a selective advantage in function such as proliferation and survival, proceed neutral without any effects, or has negative cell damaging effects. Thereby, the fitness of a neoplastic cell is affected by the interactions with itself and other cells in its microenvironment competing with one another for the available resources. Tumor heterogeneity has mainly been described at a genetic, chromosomal, or transcriptional level. The approaches used to analyze tumor heterogeneity are mostly targeted either focusing on the distribution of a single molecule in tissues such as proteins by using immunohistochemistry, or provide detailed molecular insight in tumor subpopulations by the targeted selection of tumor subpopulations. However, selection of representative tumor areas leads only to an average picture which describes the most dominant clone and therefore underestimates the extent and pattern of clonal heterogeneity. MALDI MSI has demonstrated its suitability to study tumor heterogeneity in its native microenvironment.

Helmholtz Munich

Endocrine Pathology

In situ metabolite MALDI imaging offers enormous clinical potential by enabling the imaging of a largely previously intractable class of biomolecules. Combined with known metabolic pathways, this approach provides a means to image the activities of the pathways in tissues. The endocrine system is a collection of glands that secrete hormones directly into the circulatory system. The MALDI imaging based endocrinology project fills the heuristic gap to visualize the distributions of hormones, metabolites and drugs within tissues. Recently, tissue metabolomic studies have been initiated on adrenal tissues, which have revealed a refined functional structure beyond classical histological anatomy in human adrenal glands (Sun et al. Endocrinology, 2018 PubMed). Future developments will extend the so far existing clinicopathologic application areas by imaging the activities of pathways in tissues, imaging of hormones (steroids, catecholamines), drugs and their metabolites in the cortex and medulla of the adrenal glands and other endocrine organs of tissue from patients and animal models. The aims of these projects are to advance the understanding of the mechanism of endocrine diseases and to improve diagnosis, prognostic and therapeutic decision making.

How β-cell lose their ability to provide insulin in the progress of type 2 diabetes.
Helmholtz Munich | AAP

Diabetes and Obesity

In the field of diabetes research we focus on the morphological and molecular background of the disease in the endocrine pancreas, insulin resistance in peripheral organs and complications which are caused by type 2 diabetes to generate a deeper understanding of the disease which can be used as a new basis for interventional strategies. High-resolution mass spectrometry imaging (MALDI imaging) is used for investigating unsolved questions in diabetes research. The technology makes it possible to examine the distribution of metabolic products (cell metabolites) and many other molecular classes directly in tissue sections without the need of tissue homogenization and thus enables the generation of very high quality and complex data. In the field of diabetes research we focus on the morphological and molecular background of the disease in the endocrine pancreas, insulin resistance in peripheral organs and complications which are caused by type 2 diabetes to generate a deeper understanding of the disease which can be used as a new basis for interventional strategies. High-resolution mass spectrometry imaging (MALDI imaging) is used for investigating unsolved questions in diabetes research.

Members of AAP

Prof. Dr. med. Axel Karl Walch

Head

Ulrike Buchholz

MTLA

Claudia-Mareike Pflüger

MTLA
Portrait Andreas Voss

Dipl.-Ing. Andreas Voss

Engineer, Technical Management

Dr. Na Sun

Senior scientist

Sükriye Koccayir

Service Assistant

Qian Wang

PhD student

Chaoyang Zhang

PhD Student

Xu Yin

Dr. med. vet. Monica Tost

Recent Publications

Read more

2024 Scientific Article in Journal of Controlled Release

Liu, N. ; O'Connor, P. ; Gujrati, V.&deg ; Shelar, D. ; Ma, X.* ; Anzenhofer,P. ; Klemm, U. ; Su, X.* ; Huang, Y.* ; ... ; Feuchtinger, A. ; Walch, A.K. ; Sattler, M. ; Plettenburg, O. ; Ntziachristos, V.&deg

Tuning the photophysical properties of cyanine by barbiturate functionalization and nanoformulation for efficient optoacoustics- guided phototherapy.

Cyanine derivatives are organic dyes widely used for optical imaging. However, their potential in longitudinal optoacoustic imaging and photothermal therapy remains limited due to challenges such as poor chemical stability, poor photostability, and low photothermal conversion. In this study, we present a new structural modification for cyanine dyes by introducing a strongly electron-withdrawing group (barbiturate), resulting in a new series of barbiturate-cyanine dyes (BC810, BC885, and BC1010) with suppressed fluorescence and enhanced stability. Furthermore, the introduction of BC1010 into block copolymers (PEG114-b-PCL60) induces aggregation-caused quenching, further boosting the photothermal performance. The photophysical properties of nanoparticles (BC1010-NPs) include their remarkably broad absorption range from 900 to 1200 nm for optoacoustic imaging, allowing imaging applications in NIR-I and NIR-II windows. The combined effect of these strategies, including improved photostability, enhanced nonradiative relaxation, and aggregation-caused quenching, enables the detection of optoacoustic signals with high sensitivity and effective photothermal treatment of in vivo tumor models when BC1010-NPs are administered before irradiation with a 1064 nm laser. This research introduces a barbiturate-functionalized cyanine derivative with optimal properties for efficient optoacoustics-guided theranostic applications. This new compound holds significant potential for biomedical use, facilitating advancements in optoacoustic-guided diagnostic and therapeutic approaches.

2024 Scientific Article in BMJ Open Respiratory Research

Teixeira Alves, L.G.* ; Baumgardt, M.* ; Langner, C.* ; Fischer, M.* ; ... ; Bushe, J. ; Landthaler, M.*

Protective role of the HSP90 inhibitor, STA-9090, in lungs of SARS-CoV-2-infected Syrian golden hamsters.

INTRODUCTION: The emergence of new SARS-CoV-2 variants, capable of escaping the humoral immunity acquired by the available vaccines, together with waning immunity and vaccine hesitancy, challenges the efficacy of the vaccination strategy in fighting COVID-19. Improved therapeutic strategies are urgently needed to better intervene particularly in severe cases of the disease. They should aim at controlling the hyperinflammatory state generated on infection, reducing lung tissue pathology and inhibiting viral replication. Previous research has pointed to a possible role for the chaperone HSP90 in SARS-CoV-2 replication and COVID-19 pathogenesis. Pharmacological intervention through HSP90 inhibitors was shown to be beneficial in the treatment of inflammatory diseases, infections and reducing replication of diverse viruses. METHODS: In this study, we investigated the effects of the potent HSP90 inhibitor Ganetespib (STA-9090) in vitro on alveolar epithelial cells and alveolar macrophages to characterise its effects on cell activation and viral replication. Additionally, the Syrian hamster animal model was used to evaluate its efficacy in controlling systemic inflammation and viral burden after infection. RESULTS: In vitro, STA-9090 reduced viral replication on alveolar epithelial cells in a dose-dependent manner and lowered significantly the expression of proinflammatory genes, in both alveolar epithelial cells and alveolar macrophages. In vivo, although no reduction in viral load was observed, administration of STA-9090 led to an overall improvement of the clinical condition of infected animals, with reduced oedema formation and lung tissue pathology. CONCLUSION: Altogether, we show that HSP90 inhibition could serve as a potential treatment option for moderate and severe cases of COVID-19.

2024 Scientific Article in British Journal of Cancer BJC

Wang, J.# ; Sun, N.# ; Kunzke, T. ; Shen, J. ; Feuchtinger, A. ; Wang, Q. ; Meixner, R. ; Le Gleut, R. ; Haffner, I.* ; Luber, B.* ; Lordick, F.* ; Walch, A.K.

Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancer.

BACKGROUND: Trastuzumab is the only first-line treatment targeted against the human epidermal growth factor receptor 2 (HER2) approved for patients with HER2-positive advanced gastric cancer. The impact of metabolic heterogeneity on trastuzumab treatment efficacy remains unclear. METHODS: Spatial metabolomics via high mass resolution imaging mass spectrometry was performed in pretherapeutic biopsies of patients with HER2-positive advanced gastric cancer in a prospective multicentre observational study. The mass spectra, representing the metabolic heterogeneity within tumour areas, were grouped by K-means clustering algorithm. Simpson's diversity index was applied to compare the metabolic heterogeneity level of individual patients. RESULTS: Clustering analysis revealed metabolic heterogeneity in HER2-positive gastric cancer patients and uncovered nine tumour subpopulations. High metabolic heterogeneity was shown as a factor indicating sensitivity to trastuzumab (p = 0.008) and favourable prognosis at trend level. Two of the nine tumour subpopulations associated with favourable prognosis and trastuzumab sensitivity, and one subpopulation associated with poor prognosis and trastuzumab resistance. CONCLUSIONS: This work revealed that tumour metabolic heterogeneity associated with prognosis and trastuzumab response based on tissue metabolomics of HER2-positive gastric cancer. Tumour metabolic subpopulations may provide an association with trastuzumab therapy efficacy. CLINICAL TRIAL REGISTRATION: The patient cohort was conducted from a multicentre observational study (VARIANZ;NCT02305043).

2023 Scientific Article in Gastroenterology

Einer, C.# ; Munk, D.E.*# ; Park, E.*# ; Akdogan, B.# ; Nagel, J.*# ; Lichtmannegger, J. ; Eberhagen, C. ; Rieder, T.* ; Vendelbo, M.H.* ; Michalke, B. ; Wimmer, R.* ; Blutke, A. ; Feuchtinger, A. ; ... ; Zischka, H.

ARBM101 (Methanobactin SB2) drains excess liver copper via biliary excretion in Wilson's disease rats.

Background & Aims: Excess copper causes hepatocyte death in hereditary Wilson's disease (WD). Current WD treatments by copper-binding chelators may gradually reduce copper overload; they fail, however, to bring hepatic copper close to normal physiological levels. Consequently, lifelong daily dose regimens are required to hinder disease progression. This may result in severe issues due to nonadherence or unwanted adverse drug reactions and also due to drug switching and ultimate treatment failures. This study comparatively tested bacteria-derived copper binding agents—methanobactins (MBs)—for efficient liver copper depletion in WD rats as well as their safety and effect duration. Methods: Copper chelators were tested in vitro and in vivo in WD rats. Metabolic cage housing allowed the accurate assessment of animal copper balances and long-term experiments related to the determination of minimal treatment phases. Results: We found that copper-binding ARBM101 (previously known as MB-SB2) depletes WD rat liver copper dose dependently via fecal excretion down to normal physiological levels within 8 days, superseding the need for continuous treatment. Consequently, we developed a new treatment consisting of repetitive cycles, each of ∼1 week of ARBM101 applications, followed by months of in-between treatment pauses to ensure a healthy long-term survival in WD rats. Conclusions: ARBM101 safely and efficiently depletes excess liver copper from WD rats, thus allowing for short treatment periods as well as prolonged in-between rest periods.

2023 Review in Archives of Computational Methods in Engineering

Amador, S.*&deg ; Beuschlein, F.* ; Chauhan, V.P.* ; Favier, J.* ; Gil, D.*&deg ; ... ; Walch, A.K.

Deep learning approaches applied to image classification of renal tumors: A systematic review.

Renal cancer is one of the ten most common cancers in the population that affects 65,000 new patients a year. Nowadays, to predict pathologies or classify tumors, deep learning (DL) methods are effective in addition to extracting high-performance features and dealing with segmentation tasks. This review has focused on the different studies related to the application of DL techniques for the detection or segmentation of renal tumors in patients. From the bibliographic search carried out, a total of 33 records were identified in Scopus, PubMed and Web of Science. The results derived from the systematic review give a detailed description of the research objectives, the types of images used for analysis, the data sets used, whether the database used is public or private, and the number of patients involved in the studies. The first paper where DL is applied compared to other types of tumors was in 2019 which is relatively recent. Public collection and sharing of data sets are of utmost importance to increase research in this field as many studies use private databases. We can conclude that future research will identify many benefits, such as unnecessary incisions for patients and more accurate diagnoses. As research in this field grows, the amount of open data is expected to increase.

Previous Funding by Deutsche Forschungsgemeinschaft

Previous Funding by Bundesministerium für Bildung und Forschung

SYS-Stomach: Systemmedizinischer Forschungsansatz zur Response- und Resistenzprädiktion zielgerichteter Therapien beim Magenkarzinom

 

2. Förderperiode, Verbundprojekt Sys-Stomach / Teilprojekt 5 „In-situ Proteom und Metabolomanalyse des Magenkarzinoms“

SYS-Stomach: Systemmedizinischer Forschungsansatz zur Response- und Resistenzprädiktion zielgerichteter Therapien beim Magenkarzinom

 

1. Förderperiode, Verbundprojekt Sys-Stomach / Teilprojekt 5 „In-situ Proteom und Metabolomanalyse des Magenkarzinoms“

„MALDI-AMK - 3D MALDI Imaging zur Analyse proteomischer Marker und klinischer Wirkstoffverteilung"

„Multimodal Proteome Imaging: an Entry to Biomedical Tissue Systems Biology“

„Verbund EndoMed: Frühdiagnose von intraepithelialen Neoplasien und Karzinomen des Magens mittels molekularer Fluoreszenzendoskopie“ (Teilprojekt 4: „Identifizierung von neuen molekularen Zielstrukturen für die in vivo Bildgebung von ...

Previous Funding by others

Deutsche Krebshilfe “High throughput in situ metabolomics in adrenal tumors”

Deutsche Krebshilfe „Vergleichende lokale und systematische Proteomanalyse für die Identifizierung von Biomarkern für das Magenkarzinom“

Contact

Contact 2
Portrait Andreas Voss

Dipl.-Ing. Andreas Voss

Engineer, Technical Management